If IGFBP1 is acting beneficially, then by reducing the levels of hepatic oleic acid, either by dietary or pharmacological intervention, may be an effective form of treating HCD-induced obesity and the associated metabolic dysfunction. The gene discussed is IGFBP1; the disease is obesity due to melanocortin 4 receptor deficiency.